Drugs / amoxycillin/clavulanic acid
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05678621 | Nov 2022 → Apr 2027 expected | dysgammaglobulinemia, hematopoietic and lymphoid cell neoplasm | Monash University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amoxycillin/clavulanic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05678621 ↗ |
| Route | Oral | “Duration: 12 months. Route: PO” NCT05678621 ↗ |